gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
initi buy duchenn
initi coverag buy rate pt
promis mutation-agnost phase i/ii aav-bas gene
therapi gt duchenn muscular dystrophi dmd
era gene therapi arriv focus gt compani like
solid target genet diseas effect treatment solid
phase i/ii studi treat ambulatori
non-ambulatori children adolesc dmd dmd progress
genet disord character progress muscl degener
weak ultim lead earli mortal preclin data
murin canin model dmd shown addit
function outcom improv caus express
microdystrophin normal versu level would
repres biolog meaning increas greater
could support normal phenotyp earli treatment exondi
approv base increas dystrophin express assess
product compani recent enter clinic aav-
base dmd solid unrat
unrat give edg solid figur
solid use better-understood vector
valid system human trial sarepta vector
understand test use intramuscular/intralimb inject
use optim muscle-specif promot
local vector limit potenti system toxic
solid microdystrophin theoret superior sinc
contain dystrophin nno bind site consid import
shown perpetu patholog mous dmd model
arguabl robust preclin data best
normal key measur muscl function dmd anim
solid target broader set patient phase i/ii studi
 ambulatori non-ambulatori children adolesc
potenti due flexibl optim product offer
potenti best-in-class profil model billion
risk-adjust peak sale per figur model
penetr us dmd market take
gt share price mm year exondi use
risk solid manufacturing-rel partial clinic hold
phase i/ii high-dos cohort manufactur may arbit whether
dose safe high system dose use may
lead royalti paid delay launch assumpt
catalyst data expect
pleas refer import disclosur inform regul analyst certif found page report
price target base probability-adjust model key franchis use dcf
wacc perpetu growth impli termin ebitda multipl deriv price target
dmd npv/share assum gene therapi penetr us dmd market
penetr gene therapi market assum price
roughli equival year exondi use launch assum growth thereaft
global estim appli risk-adjust forecast bn peak sale
intern program npv/share appli vari assumpt solid intern dmd program
net cash npv/share estim solid net cash posit recent stood mm mm debt
risk achiev target price
clinic gene therapi industri despit emerg breakthrough result face import challeng exampl
long-term benefit risk yet establish although produc impress preclin data
anim model duchenn muscular dystrophi dmd guarante anim data translat human
data anticip data releas releas time fashion given focu solid dmd
rare diseas target multipl industri player clinic trial recruit could prove challeng relat issu
natur histori data dmd may yet definit enough confirm outcom evolv untreat
patient expos risk phase i/ii ignit dmd data solid may difficult expect interpret
lastli solid target broader popul dmd patient increas risk patient heterogen
regulatori rel gene therapi product ever approv human use global aav-
base gene therapi product luxturna ever approv us regulatori pathway could prove
complex and/or time consum anticip due unexpect chang leadership fda new
approach gt risk-benefit calcul setback could emerg due unforeseen safeti issu
system toxic even result dmd achiev target endpoint obtain regulatori
approv risk-adjust project price target would expos downward revis anoth risk
approv may narrow indic expect may subject costli post-approv requir
intellectu properti solid util right vector may resid elsewher could caus
solid pay royalti outsid parti delay launch ip expir perhap time-frame
manufactur aav-bas gene therapi product novel complex rel difficult manufactur risk
solid see delay clinic hold develop and/or commerci product solid
develop suffici manufactur capac sale could materi constrain
competit dmd unrat investig differ approach aav-bas gene therapi
dmd nationwid phase trial micro-dystrophin nationwid
phase trial micro-dystrophin gnthon preclin develop also
phase i/ii trial dmd sarepta also discovery-stag program
collabor duke univers util gene edit dmd though see import
advantag solid sarepta competit could emerg better data anticip
financ compani may need rais addit capit may result sharehold dilut
stock price volatil share price volatil common development compani biotechnolog sector
solid bioscienc inc life scienc compani focus sole develop portfolio candid
life-chang potenti duchenn muscular dystrophi dmd center excel dmd solid
bring togeth lead expert scienc technolog medic care help progress program across scientif
platform correct therapi disease-modifi therapi diseas understand assist devic solid
lead candid adeno-associ viral aav base gene therapi current phase i/ii
ignit dmd clinic trial dmd patient age restrict base patient underli
dystrophin gene mutat incorpor base cambridg
page
summari may provid long term mobil surviv benefit dmd
risk cgtf approach overal thesi
ytd vivo genet medicin market movement februari vs decemb
aav-bas gene therapi solid bioscienc buy driver upsid aav-bas gene therapi space
small rna gene therapi alnylam buy top pick srna gene therapi see uncertainti elsewher
vivo gene edit see greater upsid potenti edita buy toolgen buy
chardan gene therapi framework dmd fit framework reason well
catalyst pipelin interim phase i/ii data dmd due
dmd estim bn risk-adjust sale
dmd neuromuscular degen diseas primarili affect young male
improv muscl function patholog multipl anim model dmd
natur histori studi dmd reveal devast ultim fatal diseas cours
solid like overcom technic hurdl plagu prior
see import advantag solid sarepta product
surrog gene therapi exon skip us less robust dmd solut
duchenn muscular dystrophi estim mm sale
potenti reduc fibrosi extend durat ambul
appendix gene therapi primeran introduct vivo gene therapi
gene therapi gt alter genet materi potenti cure diseas
vector gene therapi somat gene therapi replac genet materi
gene edit somat gene therapi modifi genet materi
rnai somat gene therapi silenc gene express
futur direct winner loser determin along certain dimens
sale key product
page
summari may provid long term mobil surviv benefit dmd
initi coverag buy rate potenti best-in-class
medicin progress fatal muscular degener weak duchenn muscular dystrophi dmd dmd
rare x-link diseas incid roughli male calcul yield approxim
preval dmd case unit dmd patient born normal muscl function howev
mutat gene encod dystrophin patient eventu present muscl weak age
diseas progress afflict individu typic wheelchair-bound age see earli mortal
cardiac lung complic standard care dmd includ corticosteroid
treatment shown slow muscl degener extend ambul year produc
numer side effect due limit clinic evid product exondi condit approv
us europ solid phase i/ii product candid aav-bas gene therapi gt
design express microdystrophin skelet cardiac muscl figur control muscle-specif
promot gene encod dystrophin largest known human gene larg encod aav
capsid thu requir use microdystrophin maintain essenti dystrophin element figur
preclin studi solid microdystrophin construct shown improv muscl structur function
measur forc gener endur injuri repeat contract solid obtain orphan drug
design odd us pediatr diseas design rpdd solid novemb
start random control open-label single-ascend dose phase i/ii trial
dmd base preclin data see reason likelihood aav-bas produc
impress result human seen anim launch aav-bas think
market-lead profil due solid choic vector muscle-specif promot
microdystrophin treatment ambulatori non-ambulatori children adolesc per figur
therefor model penetr aav-bas dmd patient catch-up cohort
incid cohort benefit like extrem high part due low incid neutral ab younger
patient model solid captur share aav-bas model price million
launch roughli cost year exondi therapi model billion risk-adjust forecast
import catalyst ahead particularli emerg first phase i/ii data see figur
interim result phase i/ii ignit dmd trial
march primari complet date phase i/ii ignit dmd trial
initi pivot trial assum posit data phase i/ii and/or seek acceler approv
regulatori approv launch acceler approv achiev
promis profil drive risk-adjust billion forecast although
challeng treat dmd gt describ later risk section note sever characterist
us offer potenti solid achiev compel result transform dmd manag
fda-approv therapi dmd usabl subset patient debat efficaci
septemb fda grant exondi unrat sarepta acceler approv pend
rodino-klapac lr et al gene therapi duchenn muscular dystrophi neurol
note older preval data reli date life expect data dmd life expect increas past decad
page
result phase trial better demonstr clinic benefit exondi long-term once-weekli
iv exondi use patient genet mutat make amen exon
skip contrast one-tim iv aav-bas gt could solut dmd patient variou mutat
dmd overal fit chardan gene therapi framework cgtf figur framework proven
predict call potenti aav-bas gene therapi space acknowledg key
unknown discuss later feel reason chanc success sinc fit framework
target monogen diseas dmd clear phenotyp rel small amount protein
 would signific durabl express possibl cur use vector tropic
skelet cardiac muscl suitabl deliveri method iv infus protein express canin
studi discuss later shown drive microdystrophin express normal
system administr aav vector via intraven iv infus success human trial
although yet mani exampl aav administ system treat muscle-rel diseas
indic approach work exampl audent therapeut unrat us shown
earli posit result target x-link muscular diseas use vector deliv intraven note
also breakthrough result shown avexi buy use vector deliv intraven
treat spinal muscular atrophi type diseas motor neuron muscl tissu
phase i/ii trial measur approv endpoint carri pivot trial
exondi acceler approv approv decis base surrog endpoint increas dystrophin
express solid phase i/ii trial measur microdystrophin protein muscl biopsi
co-primari endpoint along variou safeti endpoint compani also gather data muscl function
strength includ data cardiac respiratori function improv motor function particularli assess
meter walk test like approv endpoint gather data phase i/ii studi may inform
pivot trial design facilit regulatori interact indic earli potenti function
could prove long-term solut given histori aav gt preclin anim data aav gt
test grow number model evid mount approach could provid durabl
solut treat diseas non-human primat model shown protein express terminally-
differenti cell central nervou system although solid yet data
regard durabl human preclin test dog involv follow demonstr
sustain robust express microdystrophin singl administr muscl cell activ
divid durat aav effect long-last mirror durabl seen far trial
think lead profil due solid choic vector muscle-specif
promot microdystrophin target ambulatori non-ambulatori children adolesc
origin product/diseas exemplar cgtf breakthrough therapi design and/or prime design
chardan uniqu predict mydicar heart failur wet failur
expert believ restor dystrophin clinic signific exondi approv modul
mendel jr et al single-dos gene-replac therapi spinal muscular atrophi nejm
sehara et al persist express dopamine-synthes enzym year gene transfer primat model parkinson
page
adapt websit chardan
figur solid microdystrophin construct mimic dystrophin therebi restor anchor actin cell membran patient dmd
adapt websit chardan
figur aav-deliv solid microdystrophin construct ration design critic compon full length dystrophin
page
risk cgtf approach overal thesi
dmd mani mutat lead phenotyp could unexpect consequ solid although
dmd monogen diseas mani distinct mutat dystrophin gene lead diseas phenotyp
dystrophin gene longest known human genom megabas mb compar averag gene
length kilobas kb numer hot spot mutat lead dysfunct protein
evid suggest variat present progress diseas base specif dystrophin
aav-bas gene replac abl restor function regardless underli mutat
risk certain diseas variant amen rescu microdystrophin other may also
compet effect truncat mutant gene product could interfer function
microdystrophin unexpect process within cell disrupt microdystrophin express local
solid replac entir gene differ clinical-stag gene therapi dystrophin gene
mb long far larg encod aav capsid capac kb develop gt suitabl
deliveri via aav scientist identifi dystrophin protein domain could provid function microdystrophin
complex though suffici restor function anim model diseas may lack critic function deliv
human current multipl truncat dystrophin construct sarepta unrat
test clinic figur figur although believ solid construct better design lead breakthrough
dmd result compet microdystrophin construct may function like wild type dystrophin protein
dmd diseas develop mani year could make difficult see improv phase i/ii trial
natur histori dmd discuss greater detail later indic take year diagnosi around age
loss ambul approxim age even longer loss ambul death although solid co-
primari endpoint increas dystrophin level easili determin observ period
phase i/ii trial metric like muscl function chang cardiac respiratori function may less like show
improv rel short time-frame simpli arrest dmd diseas progress improv
overal diseas state interpret posit function data may also confound solid phase i/ii trial enrol
ambulatori non-ambulatori patient though heterogen would increas import breakthrough
data emerg risk heterogen could weaken efficaci signal patient respond better other
select vector made base data anim model may repres human
preclin model provid desir level express skelet muscl suffici express
heart warrant studi human may case though anoth vector would suitabl despit
anim model data exampl sever vector tropism muscl heart tissu includ
kol comment us construct test preclin model
reach skelet muscl heart effici context note modifi vector
use sarepta nationwid children hospit microdystrophin trial properti
vector good bad us far less well elucid
taylor pj et al dystrophin gene mutat locat risk cognit impair duchenn muscular dystrophi plo
magri et al genotyp phenotyp character larg dystrophinopath cohort extend follow-up journal
page
amount dystrophin need therapeut effect dmd may higher expect diseas like
hemophilia well understood therapeut threshold must cross prevent bleed episod
dmd howev less well understood proport normal dystrophin express must restor show
improv multipl studi use preclin human carrier model suggest express dystrophin
normal suffici prevent base kol feedback believ increas protein
expression/act aav-bas gt would repres clinically-meaning advanc current therapeut option
note treatment exondi sarepta conditionally-approv exon skip drug mean express
dystrophin normal increas pre-treat baselin base exondi
level exondi may may biolog meaning increas protein level meaning risk
microdystrophin would lessen remain seen whether aav-bas improv upon level
reach necessari yet undefin threshold reassur preclin data canin golden retriev
muscular dystrophi grmd studi indic drive protein product normal variou muscl
group said critic valid similar suffici prevent diseas human
high dose vector need dmd may unforeseen safeti consequ lack clinic hold resolv
anoth difficulti treat dmd high amount aav vector vg/kg need achiev microdystrophin
express across relev muscl high dose util wide studi lower dose requir
organ mean may risk yet encount space approach requir high
dose vector system deliveri significantli challeng manufactur perspect approach
requir much less vector due local deliveri subretin inject inde fda shown concern
manufactur regard higher dose cohort solid phase i/ii clinic trial place partial clinic hold
portion may relat death nhp solid glp toxicolog studi singl anim
euthan recov anesthet procedur solid believ event attribut procedur
error note glp toxicolog data review fda part solid ind packag addit
concern specif solid rais gt luminari dr jim wilson recent publish studi demonstr
toxic high dose vector larg anim dr wilson contextu find recent
forb interview state safeti profil aav respect immun toxic remark qualit
better experi deliveri platformsthat chang mind
applic contempl still expect pretti good safeti profil howev dose get
high believ potenti dose limit toxicityat end day best right
dilig non-clin model determin dose would see benefit similarli dose
would see dose-limit toxic select diseas unmet need signific would justifi
risk although littl evid caus alarm use human safeti appli high
vector dose remain risk need consid examin solid approach treat dmd
neri et al dystrophin level low suffici avoid muscular dystrophi human neuromuscular disord
chamberlain js dystrophin level requir genet correct duchenn muscular dystrophi basic appli
hinder et al sever toxic nonhuman primat piglet follow high-dos intraven administr aav vector
express human smn human gene therapi ahead print
hordeaux et al neurotrop properti aav-php limit mice molecular therapi ahead print
page
ytd vivo genet medicin market movement februari vs decemb
corpor report factset chardan note mention stock unrat unless otherwis state
figur select ytd price movement februari vivo gm perform aav srna ivg
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm adverum genet rna therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm solid bioscienc inc
aav-bas gene therapi solid bioscienc buy driver upsid aav-bas gene therapi space
corpor report factset chardan note mention stock unrat nr unless otherwis state bold target market cap model current market cap refer
partner product avexi lysogen wet hofh phase i/ii trial
figur aav gtwe prefer nightstar therapeut buy buy buy uniqur buy greater potenti drive upsid entir aav-bas gt space
page
targettargetccmphas ofpric ccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighhighp shareshareof genet technolog privat aav-bas genetherapi companiesestev horama meiragtx limited/athena vision solid bioscienc inc
small rna gene therapi alnylam buy top pick srna gene therapi see uncertainti elsewher
corpor report factset chardan note mention stock unrat unless state abu rgl sln-gb target market cap model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna therapi space
page
targettargetccmphas ofpric ccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighhighp shareshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot benitec biopharma marina biotech addit unrat public compani
vivo gene edit see greater upsid potenti edita buy toolgen buy
corpor report factset chardan note mention stock unrat nr unless otherwis state target market cap model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiescarib scienc egenesi excis exon feldan poseida precis scienc recombinet solid scienc inc
chardan gene therapi framework dmd fit framework reason well
corpor report chardan note mention stock unrat unless otherwis state disclosur rate neutral neg aavl time data avx buy buy qure buy
figur chardan gene therapi framework suggest approach though riski reason chanc yield clinic success ignit dmd phase i/ii studi
page
organizationdata releasedd datamonogen diseas chosen clear suitablephenotyp express effect tropic vector promot suitabl deliveri phase i/ii data spinal muscular atrophi type sma btd cnsivspark phase data inherit retin diseas btd due retinasubretin injectionbluebird biolentiglobin phase data sickl cell beta thalassemia major btd bs/bsye sever scd -thalassemia majoryes/no hbay lentiviru stem cellsex vivo st jude ucl durabl effect seen human liver hemophilia btd prime subject activ roughli normal btd deriv liverivfailuresavalanch phase iia data wet age-rel macular retinasubretin injectioncelladon corporationmydicar phase ii data advanc heart ii iv cardiacintra-coronari phase ii data parkinson cnsbi-later ic one-tim injectionssolid bioscienc shown preclin success creat promis humanssolid preclin data duchenn muscular mutat howev vari impair possibleveri like perhap express benefit skelet diaphragm cardiac muscl tissuesivdiseas geneticsdeliveri solid bioscienc inc
catalyst pipelin interim phase i/ii data dmd due
corpor report chardan note mention stock unrat unless otherwis state
figur catalystssolid seek produc preliminari phase i/ii data time-frame
page
dateeventchardan competit pcd trial ns pharma patient amen exon skip weekli competit phase result wave antisens oligo chemistri exon skip patient natur histori pcd gnthon observ studi began patient potenti treatabl exon competit interim pi/ii data sarepta dmdwe note solid optim vector promot competit interim pi/ii data sarepta dmdsurrog still need consider amount mab begin vivo preclin studi miceth ab could stabil could reduc muscl iv manufactur scale current capac consid increas iv fda respons high-dos clinic hold impact clinic develop activ low-dos competit pcd phase confirmatori trial sarepta exondi exondi condit fda approv evid efficaci competit pcd phase trial sarepta exon skip goal durabl efficaci iv interim phase i/ii ignit dmd resultsfirst chanc human poc result microdystrophin competit pcd phase trial sarepta antisens oligo patient amen exon natur histori pcd ucl observ studi began mutat criteria enrol design aid exon skip natur histori pcd cinrg observ studi began studi patient observ time year in-depth mab file ind dmd mutat ab could stabil could reduc muscl competit interim result wave ole efficaci trial find wave approach iv pcd phase i/ii ignit dmd studi pt age endpoint chang -di competit pcd phase ib trial dmdsimilar aav differ -di construct patient sever ignit competit pcd pi/ii trial sarepta dmdsurrog gene therapi compensatori overexpress competit pcd pi/ii trial sarepta pt enrol cohort children test follow year iv expect licens patent expiri datepat cover structur element microdystrophin iv expect pend patent expiri datepat cover promot compon construct yet issued-di microdystrophin dmd duchenn muscular dystrophi gt gene therapi ol open label pcd primari complet date endpoint poc proof concept solid bioscienc inc
figur solid pipelin dedic singular indic dmd take vari approach treat cure diseas aav-bas gt neutral antibodi
page
product candidatenear-term milestonesww rightsproduct candidatenear-term milestonesww rightssolid biosciencessolid suitsoft wearabl assist devic exoskeleton duchenn muscular dystrophi mabduchenn muscular dystrophi dmd begin preclin studi candid select assay developmentsolid biosciencessolid gene therapi iv duchenn muscular dystrophi dmd interim data phase i/ii ignit dmd trial pcd phase i/ii ignit dmd trialstag developmentpreclinphas
figur dmdwe model launch rapid uptak one-tim us price million us excerpt
page
million unit state sale million sale yoy statespopul rate per per year per year male incid male preval patient exist incid cohort patient aliv gt pt catch-up cohort treat treat gt treat cohort patient diagnos gt launch cumul incid cohort treat treat gt treat cohort patient diagnos gt launch yearli newly-diagnos patient treat newli treat gt treat patient treat gene therapi catch-up incid patient newly-tr gene catch-up incid gene therapi cumul treatment dmd share gene market share market share sarepta -di market share patient treat price sale yoy pay-for-perform model link compani financi cumul dmd patient treat still gt durabl pay sale solid bioscienc inc
dmd estim bn risk-adjust sale
dmd neuromuscular degen diseas primarili affect young male
duchenn muscular dystrophi dmd x-link degen diseas lead progress muscl
dmd caus mutat dmd gene encod dystrophin protein mutat lead loss
dystrophin product dystrophin critic compon complex anchor muscl cell actin cytoskeleton
cell membran extracellular matrix figur connect help provid maintain structur
protect muscl injuri contract extens absenc dystrophin progress
deterior muscl function due inabl repair muscl cell repeat contract extens dmd
patient lead loss ambul ultim death diagnosi dmd current occur around age
howev minim invas newborn screen develop current estim suggest incid
male birth solid estim total us patient popul howev see higher
estim publish calcul higher preval base epidemiolog formula
adapt fairclough rj et al chardan
figur dystrophin anchor actin filament extracellular matrix interact sarcoglycan dystroglycan complex
editor genereview internet seattl wa univers washington seattl
investig ear glucocorticoid therapi design protocol method use muscl nerv
faircough rj et al therapi duchenn muscular dystrophi renew optim genet approach natur review
page
pre-exondi dmd cost societi per year per patient billion year us aggreg
due loss peripher limb function ambul patient dmd creat substanti econom burden
societi direct cost healthcar patient well indirect cost famili lost wage household
adapt etc estim suggest direct cost per year household burden
somewher per figur gener prior launch exondi
dmd present childhood skelet muscl weak progress critic respiratori cardiac
earliest sign dmd typic delay development mileston earli childhood delay independ
sit stand diagnost metric includ examin sever stereotyp present includ abnorm
gait walk tip-to gower sign use arm rise prone posit addit featur dmd includ
elev serum creatin kinas abnorm muscl biopsi final confirm genet test time limb
continu weaken gener necessit wheelchair age muscl weak result muscl injuri
properli repair absenc dystrophin lead muscl death fibrosi addit fat
deposit patient continu degener rapidli second decad typic succumb cardiac
respiratori failur due loss muscl function birthday addit loss muscl function dmd
patient present certain cognit defect includ reduc verbal iq memori attent
dmd caus mani mutat dmd gene similar clinic dmd gene
encod kda dystrophin protein largest known singl gene human genom cover mb
exon leiden muscular dystrophi page curat mutat report literatur current
databas compil public variant uniqu mutat delet larg
section dmd gene result gene correct read frame incompat exon splice
thu encod truncat dysfunct protein dmd also caus smaller mutat includ point
mutat duplic rarer certain region dmd gene identifi hot spot
mutat like occur commonli mutat portion gene exon figur
standard care limit corticosteroid exondi new addit
prednisone/prednisolon deflazacort shown slow loss strength muscl function dmd patient
respiratori function also stabil may cardiac benefit initi treatment typic coincid
plateau motor skill prolong muscl function delay onset declin phase diseas steroid
typic continu even loss ambul preserv upper limb trunk strength well respiratori
cardiac function evid specif mutat dmd may determin whether corticosteroid provid
benefit exon mutat show greatest proport treat patient experienc prolong
howev larger bodi evid suggest overal natur histori also improv
product recent newli market dmd us eu despit clinic benefit appear
landfeldt et al burden duchenn muscular dystrophi neurolog
perum ar et al neuropsycholog profil duchenn muscular dystrophi appli neuropsycholog child
aartsma-ru et al entri leiden duchenn muscular dystrophi mutat databas overview mutat type
paradox case confirm reading-fram rule muscl nerv
bushbi et al diagnosi manag duchenn muscular dystrophi part diagnosi pharmacolog
bello et al dmd genotyp loss ambul cinrg duchenn natur histori studi neurolog
houd et al deflazacort use duchenn muscular dystrophi follow-up pediatr neurolog
matthew et al corticosteroid treatment duchenn muscular dystrophi cochran databas system review
page
limit far exondi achiev acceler approv fda exondi
intend improv protein product patient mutat correct skip exon translarna
unrat approv eu us understand fda may
point reconsid product approv translarna facilit translat dystrophin past prematur stop codon
induc mutat product limit use subset dmd patient
adapt aartsma-ru et chardan
figur exon skippingonli patient aid exon skip common mutat differ drug need exon
aav gene therapi could provid mutation-agonist solut complic genet dmd sever
therapeut develop target highly-preval mutat region exampl antisens oligonucleotid
promot exon-skip bypass mutat region gene make function truncat protein figur
right exon skip commonli correct mutat compris dmd
patient exon skip account mutat target
exon skip would account dmd mutat figur left panel approach howev
necessit differ drug mutationmean patient would help individu
product inde case exondi sarepta also product develop mediat exon
skip treatment mutat agnost could use dmd patient would signific advantag
mutation-specif treatment view gene therapi truncat function form dystrophin
gene deliv via aav vector system replac non-funct mutant version tractabl
solut gt could use patient regardless underli caus mutat aav-bas gt approach
current investig compani identifi figur
addit microdystrophin deliveri via aav-bas gt compani work test efficaci
surrog gene therapi see discuss non-dystrophin protein deliv compens lack
dystrophin muscl cell gene brought clinic encod galnac transferas
fst encod follistatin evid protein act muscl cell modul membran
protein complex absenc dsytrophin albeit mechanist differ way whether surrog gene
therapi approach effect microdystrophin deliveri remain seen
aartsma-ru et al less therapeut exon skip duchenn muscular dystrophi lancet neurolog
page
improv muscl function patholog multipl anim model dmd
microdystrophin construct uniqu size dmd gene present signific problem
develop dystrophin gene therapi treat dmd howev discov patient becker
muscular dystrophi much less sever diseas patient live sometim beyond
markedli better muscl function dmd patient express naturally-occur truncat form
dystrophin result research began experi shorter version dystrophin develop construct
could packag deliv aav vector develop microdystrophin figur
contain spectrin-lik repeat found full-length protein repeat flank actin
bind domain dystroglycan bind domain make construct mimic essenti function
dystrophin size kb accommod kb aav capac along abil anchor actin
extracellular matrix solid microdystrophin maintain bind site neuron nitric oxid synthas nno loss
nno identifi patholog factor dmd restor bind site microdystrophin
construct could improv outcom provid advantag solid mini- microdystrophin
remaind solid microdystrophin construct includ synthet muscle-specif promot ensur
correct local express construct packag vector tropism skelet cardiac
muscl anim model dmd also well known cross blood-brain barrier confer tropism
adapt chardan
figur solid microdystrophin contain actin bind domain repeat nno bind site dystroglycan bind domain
mdx mous model microdystrophin administr improv muscl patholog administr
aav-di design use gene sequenc canin dystrophin
dystrophin-defici mdx mice drove express microdystrophin sever muscl group includ quadricep
gastrocnemiu heart skelet muscl histolog demonstr appropri local member dystrophin-
associ complex figur includ -dystroglycan sarcoglycan protein well normal level
muscular nno activ aav-di administr also improv muscl function healthi level allow significantli
less rapid declin muscl forc repeat contract compar mdx mice receiv treatment
figur similar experi treat mice human construct demonstr compar efficaci
measur abil mdx mice run treadmil figur week post-administr mice
high express microdystrophin could run significantli
hakim ch et al five-repeat micro-dystrophin gene amelior dystroph phenotyp sever model
duchenn muscular dystrophi molecular therapi method clinic develop
lai et al dystrophin carri spectrin-lik repeat anchor nno sarcolemma enhanc exercis perform
mous model muscular dystrophi journal clinic investig
hakim ch et al five-repeat micro-dystrophin gene amelior dystroph phenotyp sever model
duchenn muscular dystrophi molecular therapi method clinic develop
page
adapt hakim ch et al chardan
figur aav-di version prevent rapid forc decreas restor forc decreas healthi level mdx mice
adapt chardan
figur mdx mice restor express multipl muscl group improv treadmil run distanc
dog treat canin microdystrophin also demonstr markedli improv muscl golden retriev
muscular dystrophi grmd anim model understand close mimic human diseas due point
mutat dmd gene grmd anim produc truncat non-funct dystrophin protein present similar
progress muscl weaken includ cardiac muscl involv deliv canin microdystrophin construct
design grmd anim show robust biodistribut sever muscl group vector also
found non-muscl tissu express restrict due inact promot non-muscl
page
site mous model administr canin version improv muscl function measur
increas extens torqu flexion torqu day post treatment figur
adapt chardan
figur administr canin version grmd anim improv muscl function compar untreat anim
natur histori studi dmd reveal devast ultim fatal diseas cours
mani studi examin cours muscl degener dmd describ
caus gene known sinc result cours diseas rel well character
patient typic present earli childhood age delay motor mileston sign
abnorm gait plu frequent fall dmd boy still make function gain stage particularli use
glucocorticoid time diagnosi howev patient begin plateau develop onset
plateau phase vari last month year plateau loss function becom notabl
patient declin rapidli patient treat steroid loss ambul typic occur
year age steroid treatment usual occur closer age wheelchair-bound patient
continu declin scoliosi worsen well self-feed respiratori cardiac capabl prior
advent steroid therapi patient typic pass away teenag year modern intervent includ
steroid use ventil muscular dystrophi associ cite surviv earli becom
common case men live thu calcul preval data sinc much
data literatur reli date assumpt life expect
patient die birthday figur clear document diseas trajectori dmd fatal
patient enter declin phase diseas spontan improv
on-going natur histori nh studi could continu inform understand specif diseas metric although
robust bodi data cours dmd least natur histori studi current on-going
investig era glucocorticoid therapi design protocol method use muscl nerv
treatment preserv clinic meaning function mileston reduc rate diseas progress measur manual muscl
test commonli use clinic trial outcom measur muscl nerv
page
clinicaltri gov goal studi strictli map diseas
cours rather assess novel metric use inform clinic trial design endpoint includ
walk test qualiti life assess potenti serum biomark one on-going nh studi
conduct cooper intern neuromuscular research group cinrg produc numer public
detail novel genet modifi dmd pathogenesi new metabol serum biomark diseas import
assess impact cardiomyopathi corticosteroid patient outcom thu see valu new studi
adapt cm et al chardan
figur natur histori dmdpatient often see loss ambul around year age death age
solid like overcom technic hurdl plagu prior
solid initi phase i/ii trial novemb plan interim readout trial
treat patient age although trial open label design patient
random dose cohort delay treatment control group month patient
delay treatment group given infus although higher dose vector yet
disclos studi singl ascend dose studi low- understand dose vg/kg mid-
page
high-dos cohort first round patient treat toward older end studi popul year
old children year old dose later studi data safeti monitor board meet ensur
safeti therapi discuss low dose cohort process time fda concern
regard manufactur dose high-dos cohort place arm studi partial clinic
hold prospectu solid state expect abl address specif defici identifi fda
submit addit inform demonstr manufactur capac product attribut support
high-dos group compani intend submit respons fda address specif defici near
futur fda day respond compani expect overal time clinic
develop affect partial clinic hold follow issu particularli consid
recent warn dose-depend anim toxic certain aav variant base data describ dr jim
wilson far human high-dos aav vector administr shown favor risk-reward dynam
adapt chardan
figur grmd model solid canin construct lead t-cell respons even high dose
associ immun issu troubl earlier outdat aav-bas technolog dmd
area signific interest gt mani year awar aav-bas therapi use outdat
technolog tri clinic limit success exampl phase studi run
nationwid children hospit nch asklepio biopharma unrat
construct administ via intramuscular inject strategi achiev sustain express
minidystrophin potenti due elev t-cell respons construct and/or preexist immun
aav elimin concern solid trial immun respons studi extens
canin model found caus detect t-cell respons month post-administr even
highest dose figur patient phase i/ii trial screen preexist capsid immun anti-
antibodi may caus aberr respons prior enrol although guarante
respons human suggest solid vector improv chanc success previou attempt
hinder et al sever toxic nonhuman primat piglet follow high-dos intraven administr aav vector
express human smn human gene therapi ahead print
mendel jr et al dystrophin immun duchenn muscular dystrophi new england journal medicin
bowl de et al phase gene therapi duchenn muscular dystrophi use translat optim aav vector molecular
page
like overcom deliveri issu earlier product note also small
trial intramuscularly-administ vector use
sarepta/nationwid trial result yet avail see intramuscular administr
effect rout deliveri system diseas like dmd iv administr possibl suspect due
improv vector manufactur avail tropic vector muscl tissu avail
muscle-specif promot see iv administr like succeed
see import advantag solid sarepta product
solid use microdystrophin construct theoret better competitor
microdystrophin construct perhap uniqu preserv nno bind site repeat full-length dystrophin
figur figur knowledg element contain respect construct use pfizer
origin develop compani sarepta/nationwid children hospit
collabor figur also found gnthon unrat also partnership use
microdystrophin construct nationwid preclin test howev program employ synthet
promot vector base preclin find duan lab univers
missouri loss nno contribut muscl patholog seen dmd reduc blood flow contract
caus ischemia addit inclus nno bind site microdystrophin hypothes
improv muscl function like wild type healthi muscl construct also evid function
heterogen among differ protein domain contain differ mini- microdystrophin preclin
result suggest construct contain hing restor muscl morpholog function better
contain hing may put sarepta construct disadvantag compar figur
solid produc better data preclin function assay compar express mini- microdystrophin
construct mdx mous model appear compar level dystrophin-posit fiber stain could
suggest solid sarepta construct may level function figur note howev
function assay muscl forc measur repeat cycl lengthen solid microdystrophin fulli
restor wild type level forc mdx mice sarepta/nationwid construct lead signific
improv untreat mdx mice muscl still weaker wild type counterpart figur
accept caveat compar differ preclin trial differ may immateri
le guiner et al long-term microdystrophin gene therapi effect canin model duchenn muscular dystrophi natur
lai et al dystrophin carri spectrin-lik repeat anchor nno sarcolemma enhanc exercis perform
mous model muscular dystrophi journal clinic investig
harper sq et al modular flexibl dystrophin implic gene therapi duchenn muscular dystrophi natur medicin
bank gb et al polyprolin hing influenc function capac truncat dystrophin plo genet
function mdx mice human gene therapi
hakim ch et al five-repeat micro-dystrophin gene amelior dystroph phenotyp sever model
duchenn muscular dystrophi molecular therapi method clinic develop
page
adapt corpor present chardan
figur solid construct contain repeat requir nno bind exclud concern
solid select ambulatori non-ambulatori patient increas reward risk program per
figur note solid broader program introduc risk describ previous howev
vector muscle-specif promot microdystrophin construct optimizeda believ
choic solid may logic creat broader initi market opportun solid peer also
believ presenc age-match control arm delayed-treat control provid uniqu opportun
figur solid overal approach us impli market leadership sarepta aav-bas dmd
page
namephaseprimari complet datetri designvectorpromotertransgenecommentsolid ol monthsm synthet muscl creatin kinas includ nno bind site includ hing inclus nno bind exclus hing provid greatest chanc restor full-length dystrophin function highli inclus trial ambul weight limit clinic trial includ age-match control arm delayed-treat yearsm old ambulatori weight hing includ nno bind site hing improv muscl patholog compar hing howev lack nno bind may reduc function benefit trial includ subset patient base ambul weight criteriasarepta yearsm averag motor skills/ heavi chain enhanc plu muscl creatin kinas enhancer/promotermicro-dystrophin includ hing includ nno bind site hing anim model improv muscl pathology/funct may deleteri lack nno bind may reduc function benefit micro-dystrophin administrationsarepta yearsm average muscl creatin kinas gene compensatori utrophin express altern approach truncat dystrophin administr preclin model suggest benefit approach yet establish robustli
adapt hakim ch et al watchko et al corpor present chardan
figur mdx mice construct well express tibiali anterior muscl restor wild-typ level dystrophin posit fiber
adapt hakim ch et al watchko et al corpor present chardan
figur mdx mous model solid microdystrophin us restor muscl function wild type level better competitor product
page
surrog gene therapi exon skip us less robust dmd solut
surrog gene therapi may util set microdystrophin appli given size
dmd gene investig turn surrog gene therapi surrog gene therapi involv deliv
compensatori gene rather mutat absent gene drive diseas case dmd differ surrog
gt approach attempt follistatin myostatin antagonist hypothes improv muscl
growth util clinic trial phase studi patient becker muscular dystrophi
vector contain human follistatin control cmv promot deliv intramuscularli found improv
result year post small phase i/ii trial follistatin dmd run nationwid
children hospit privat conclud novemb result understand pend
trial also nch collabor sarepta explor use aav-deliv dmd
encod galnac transferas enzym catalyz addit sugar residu protein
neuromuscular junction critic interfac muscl function activ creat linkag anchor
membran dystroglycan complex extracellular matrix overexpress howev promot
express member complex includ utrophin -dystroglycan beyond neuromuscular junction
throughout muscl lead benefit similar replac dystrophin inde mdx mous model
gene therapi phenocopi microdystrophin gt non-human primat also saw increas express
muscl membrane-associ protein throughout muscl although may preclin evid
administ surrog gene strategi yet investig thoroughli microdystrophin deliveri
us like succeed howev consid surrog strategi might benefit patient
exist immun dystrophin protein could preclud use microdystrophin gt patient becker
muscular dystrophi might benefit overexpress muscl membran complex
aav-bas gene therapi durabl broadly-applic solut exon skip given
dystrophin express shown far exondi comparison produc microdystrophin
rang normal canin think aav-bas like superior approach dmd
note follow drug sarepta golodirsen mediat exon skip phase trial also
shown increas dystrophin recent place brief clinic trial hold uk patient
experienc rhabdomyolysi although import improv antisens oligonucleotid chemistri innov
compani like unrat may bring promis exon skip dmd closer aav
chronic dose approach need separ drug caus mutat figur may continu
give edg aav-bas may benefit combin therapi includ exon skip pre-
treatment gene therapi promis durabl univers gene therapi us appeal option
mendel jr et al phase follistatin gene therapi trial becker muscular dystrophi molecular therapi
martin pt et al overexpress skelet muscl prevent injuri result eccentr contract mdx
chicoin lg et al vascular deliveri gastrocnemiu muscl rhesu macaqu stimul
express dystrophin laminin surrog molecular therapi
page
duchenn muscular dystrophi estim mm sale
potenti reduc fibrosi extend durat ambul
earli preclinical-stag monoclon antibodi target latent tgf bind protein mous
model dmd genome-wid scan gene may also contribut patholog diseas progress identifi
diseas subsequ studi human diseas confirm find use patient unit
dystrophinopathi cohort research determin particular mutat gene stabil
protein lead increas durat ambul result strike patient also treat corticosteroid
figur result find becom target interest solid slow diseas progress
adapt flanigan km et al chardan
figur specif variant gene lead increas durat ambul particularli patient given steroid
precursor reduc fibrosi mous model dmd identifi role
modifi diseas research examin mechan action express human mdx mous
model dmd model solid plan employ futur preclin studi found drove
increas muscl size muscl fiber well membran damag fibrosi block activ
antibodi howev prevent fibrosi stabil manner similar protect gene variant figur
without cleavag reduc releas tgf caus agent fibrosi given result solid
begin screen antibodi candid develop biolog goal replic anim
find human reduc fatti deposit fibrot muscl lesion patient slow diseas progress
extend durat ambul
heydemann et al latent tgf-bind protein modifi muscular dystrophi mice journal clinic investig
flanigan km et al genotyp predict age ambulatori loss duchenn muscular dystrophi annal neurolog
ceco et al target latent tgf releas muscular dystrophi scienc translat medicin
page
compani target dmd use monoclon antibodi uniqu target explor
landscap clinical-stag biolog asset alter dmd progress found notabl on-going phase ii ii/iii trial
unrat test pamrevlumab antibodi connect tissu growth factor cgtf anoth pro-
fibrot molecul focu studi effect respiratori function non-ambulatori patient roch unrat
domagrozumab target myostatin inhibitor muscl growth increas
muscl size function ambulatori patient although solid asset still preclin use biolog seem
viabl strategi novel dmd treatment await preclin data model program substanti
adapt ceco et al chardan
figur block cleavag antibodi prevent muscl fibrosi mous model diseas
page
appendix gene therapi primeran introduct vivo gene therapi
gene therapi gt alter genet materi potenti cure diseas
gene therapi work modul cellular genet materi gene express treat diseas medic condit
may caus disord express function singl gene hemophilia cystic fibrosi may
multifactori heart diseas diabet parkinson diseas gene therapi broadli entail modul
dysfunct genet state within patient cell treat cure diseas deliveri function gene use viral
non-vir vector vector gene therapi direct modif dysfunct gene gene edit silenc
express gene product rna interfer rnai first situat modul
genet materi occur dna blueprint level cell therapi long-last cur third
situat current technolog achiev durabl silenc target gene product provid potenti long-
last therapeut respons usual take form introduc materi compens inact under-
express gene alter modifi silenc dysfunct gene also possibl
diseas caus defect often genet level cell center almost human cell nucleu
contain chromosom turn hous cell genet materi dna gene unit dna encod
messag protein product accomplish product messeng rna mrna
translat protein process convers dna mrna protein gener term central dogma
biolog exampl insulin receptor protein code insulin receptor gene insulin receptor protein
thereaft respons regul glucos metabol within cell fatti tissu liver organ
sever condit caus alter gene alter gene express lead alter rna protein
express alter gene gener reduc absent express increas express alter function
tradit therapi use small molecul often target protein product advanc gene therapi
techniqu brought abil interven diseas level dna mrna
treatabl genet condit aris variou error dna sequenc genet condit often diagnos
birth seriou life-threaten case howev condit pass one
gener anoth without individu show sign diseas alter gene genet condit
result error individu dna sequenc sometim term mutat disord call genet
disord mani differ type genet condit includ
single-gen monogen disord mutat caus rna protein encod singl gene
dysfunct miss thought single-gen disord hemophilia easiest treat use gt
chromosom condit chromosom condit syndrom entir larg segment
chromosom miss duplic rearrang otherwis alter
multifactori diseas multifactori diseas aris mutat multipl gene along environment
factor mani complex adult disord alzheim diseas genet environment compon
thought multifactori diseas difficult treat use gene therapi
defect gene manifest rna protein level gene undergo chang affect express function
chang transmit correspond rna gene case chang rna
transmit onto correspond protein gene undergo chang section gene delet
delet seen rna protein correspond gene consequ technolog like vector gene
page
therapi compens genet defect gener under-express inact gene technolog like
gene edit rnai modifi silenc genet defect gener over-express dysfunct gene
genet condit togeth common thu creat larg address opportun gene therapi genet
condit aggreg common exampl cystic fibrosi genet condit affect lung
digest system affect roughli individu roughli new case diagnos year
individu hundr addit rare ultra-rar diseas lipoprotein lipas defici
known genet compon addit mani cancer show strong genet compon brca mutat
breast ovarian cancer therefor case vast number patient across mani condit may benefit
gene therapi option avail
gene therapi repres potenti durabl solut old diseas problem vector gene therapi gene edit
alter genet materi cell approach provid perman cur solut though rnai
perman technolog recent success rnai demonstr durabl silenc dysfunct gene
product express allow long-last therapeut respons durabl effect contrast convent
therapeut often involv provid regular infus drug sometim form miss protein
econom side gene therapi cur given therapi patient may need
medic and/or support medic care rest her/hi life durabl guarante attempt
made improv technolog solut perman long term least
gene therapi clinic target somat cell germlin gene therapi controversi germ cell
test sperm ovari egg precursor embryo earli stage concept pass genet
inform progeni non-germlin cell also call somat bodi cell includ cell liver cell lung
cell thu major group gene therapi
somat gene therapi somat gene therapi activ pursu form gene therapi
produc import clinic trial success note somat gene therapi alter pass
individu progeni thu provid treatment affect individu
germlin gene therapi advantag chang germlin genet inform chang inherit
thu provid cure gener howev germlin gene therapi prone greater risk somat
gene therapi therefor pursu activ point recent advanc technolog
first time made simpl inexpens effect fix genet defect led panel thought leader
field say given speed genom engin field evolv group conclud
urgent need open discuss merit risk human genom modif broad cohort
scientist clinician social scientist gener public relev public entiti interest
decades-long progress gene therapi disrupt safeti controversi first
attempt gene therapi made oak ridg nation laboratori tennesse
enthusiasm gene therapi increas steadili case report patient
extrem seriou condit scid disord protein metabol etc cure almost cure chang
american lung associ cystic fibrosi avail http //www lung org/assets/documents/publications/solddc-chapters/cf pdf
uc berkeley news center avail
sheridan gene therapi find nich natur biotechnolog
page
septemb jess gelsing patient diagnos mild form ornithin transcarbamylas
defici die viral-vector-associ toxic result sever immun respons infus liver
adenovir vector carri relev transgen subsequ investig reveal protocol violat failur
follow report standard advers event lead prosecut research clinic investig involv
trial time reput gene therapi compani take hit privat sector fund declin
technolog bubbl burst thu reduc fund gene therapi clinic trial final
gene therapi studi termin patient develop leukemia lead fda suspend gene therapi
trial involv hundr patient
setback enthusiasm gene therapi return due signific advanc
current excit financi market gene therapi compani consequ recent develop
technolog matur better techniqu avail reduc risk patient technolog
matur point scientist better control construct viral non-vir vector reduc
harm patient exampl less immunogen strain viral vector develop addit non-vir
vector also develop would reduc risk immune-medi reject even
breakthrough result seen recent trial patient seriou life-threaten diseas difficult-to-
treat patient exampl patient sever combin immun defici so-cal bubbl babi
extrem vulner infect benefit dramat strimv sever case partial complet
cure report lead much favor recept gene therapi compani import
advanc made spinal muscular atrophi hemophilia bmn
adrenoleukodystrophi lenti-d
regul fda ema work close academia industri support innov evid
regulatori support come earlier ema market author strimv adenosin deaminas
scid ada-scid fda follow approv first gene therapi us ex vivo kymriah
yescarta vivo luxturna addit regulatori guidanc upcom framework gene
therapi gener optim marketplac
gene therapi progress mid- late-stag pipelin furthermor mani research institut
restart respect gene therapi program feder philanthrop fund risen
consider number gene therapi compani gone public figur ipo market stock
robust promis gene therapi treat rare common diseas genet element
us fda breakthrough therapi design ema prime design pick would note
decemb drug receiv prime design gene-therapi relat good
number prime-design drug alreadi achiev us fda breakthrough therapi design
capit flow big biopharma compani increas exposur gene therapi capit
commit come form equiti partnership payment intern invest
patient advocaci group undertaken activ initi provid support group play role
connect research patient well increas awar goal acceler progress
toward find therapeut orphan diseas
page
adapt uniqur investor day slide octob new york chardan
figur past decad number gene therapi trial compani valuat increas markedli
vector gene therapi somat gene therapi replac genet materi
vector gene therapi involv deliv gene use vector appropri tissu approach vector
gene therapi involv compon transgen therapeut gene compens defect version
gene present patient cell vector allow deliveri transgen appropri cell
induct mainten transgen cell per figur devic cathet syring
deliv transgene/vector combin appropri cell vector gene therapi deliv vivo
directli bodi ex vivo bodi cell outsid bodi per figur
corpor report cite univers pennsylvania broken link chardan
figur gene therapi involv use vector get human bodi produc therapeut protein
page
kaji leiden journal american medic associ chardan
figur vector gene therapi deliv vivo directli patient ex vivo patient cell follow transplant
viral vector versu non-vir vector current import approach clinically-relev product
viral vector approxim current gene therapi trial util modifi viral vector sinc dna larg
highly-charg virus known access nucleu cell use deliv gene non-vir carrier
typic preclin develop repres technolog liposom polymer-bas deliveri
nanoparticl nake dna plasmid transfer broad viral subtyp non-integr integr
non-integr viral vector adenoviru aav hsv vaccinia adenovir vector adeno-associ viru
aav vector usual although alway remain separ divid express genet element aav
vector remain outsid host cell genom episom integr requir action happen
low frequenc aav vector use infect non-divid slowli divid
cell quickli dilut away rapidli divid cell
integr viral vector retroviru lentiviru insert recipi chromosom inherit non-
germ-lin descend cell mani bodi cell includ somat cell continu divid life
individualfor exampl skin cellsand therefor import descend cell receiv
transgen maintain treatment exampl integr viral vector retroviru vector lentiviru
technic subtyp retroviru lentivirus capabl infect non-divid activ divid cell
standard retrovirus typic infect activ divid cell earlier trial use system focus
page
shana et al coveri medicin neurobiol chardan note lentivirus subtyp retroviru
figur viral vector comparedth profil aav make ideal vector varieti gene therapi indic
varieti type viral vector see figur aav far util trial
aav vector non-integr viral vector test gene therapi wide rang disord
spinal muscular atrophi sma type parkinson diseas hemophilia congest heart failur aav famili
viral vector workhors current vector gene therapi trial given persist effect
larg number avail serotyp aav low pathogen low immunogen addit
individu aav serotyp demonstr affin differ tissu type allow precis target gene deliveri
even set system administr exampl aav-bas viral vector demonstr sustain
transgen express greater year non-human primat recent landmark st jude long-term
show transgen express human greater year singl treatment
retroviral/lentivir vector integr viral vector test gene therapi disord
primari immunodefici lymphoma beta-thalassemia leukemia lymphoma lentivirus use
success ex vivo hematopoiet cell exampl use chimer antigen receptor
compani hematolog malign unrat sickl cell diseas thalassemia major
limit lentiviru reason aav use frequent achiev suffici high viral titer
nathwani et al long-term safeti efficaci factor ix gene therapi hemophilia engl
page
adeno-associ viru aav adenovirusherpesviru lentivirustransgen kb year year primat month murin brain year humansexcellentproblematicconcernsgoodnon knownimmun respons vector helper-viru contaminationhelper-viru contaminationcan issuepotenti pathologiesassoci integrationdiseas associ parent virusnoyesyesyesinn immunitylimitedyesyesyesnononoyesless risk insert mutagenesisless risk insert mutagenesisless risk insert mutagenesismor risk insert mutagenesistransduct non-divid cellsyesyesnoyeshighli scalablescalableconcern scalabilityscal larg scale product highly-pur vector larg scale product helper-viru contamin scalabl product yet moder scale product highli pure vectoradvantag non-pathogen capsid choic affect tropism easili manipul stabl work divid cell non-divid cell non-integr high transduct effici larg transgen capac abil latent work divid cell t-cell stem cell immun responselimit small transgen work divid cell potenti immunogen transient express high inflammatori profil scalabl infect divid cell insert mutagenesi possibl immunogenicityinsert dnapathogenesisdur transgen expressionscal solid bioscienc inc
difficult addit lentivirus randomli integr genom pose risk insert critic gene
chromosom lead develop condit like cancer
adenovir vector non-integr viral vector current test gene therapi sever form
cancer pancreat cancer glioma head neck cancer esophag cancer adenovirus known
highli immunogen caus high short-term express therefor may ideal persist
effect necessari build new blood vessel heart
vaccinia viral vector non-integr viral vector test wide rang cancer
herp simplex viral hsv vector non-integr viral vector test gene therapi pain
treatment use intraderm inject nerv fiber hsv caus shingl infect nerv select
herpesviru clinic relev vector feel corneal applic may import
viral vector though widely-us non-vir vector limit
activ host immun system virus activ host immun system lead inflamm
issu jess gelsing case well long-term immunolog respons may neutral viru thu
limit durat transgen express and/or abil re-treat patient
limit size transgen viral vector accommod certain size transgen thu limit
therapi gene within size limit challeng aav use hemophilia
difficulti product particularli challeng issu common multifactori diseas
diabet current method scale produc larg quantiti reliabl
non-vir vector sometim use overcom limit viral vector non-vir method packag deliv
dna rna via variou approach exampl approach use naked/plasmid vector liposom polym gene-
activ matric potenti mean encourag transport electropor method use combin
dna packag physic method enhanc deliveri packag dna far method
less success viral counterpart advantag lead strong immun respons non-vir
vector tend simpler construct gener safer viral vector method non-vir vector also
advantag abl inject much larger volum dna viral vector limit size capsul
carri gene payload physic method enhanc uptak dna cell therapeut effect
needl jet inject nake dna plasmid involv direct inject therapeut dna molecul
organ tissu interest without encapsul result effect long-term gene
express method often use dna vaccin topic gene deliveri
hydrodynam gene transfer high pressur jet use inject larg volum dna molecul
electropor short puls high voltag use propel dna across cell membran temporarili
make cell membran permeabl
sonopor similar concept electropor except ultrasound use increas cell permeabl
gene gun dna capsul insid gold heavi metal particl deliv high ga pressur
al-dosari gao american associ pharmaceut scientist
page
natur gene chardan knowledg never use human clinic studi
figur adeno-associ viru aav serotyp preferenti tissu tropism
tropism immunogen may predict factor upcom trial import ip tropism
relat human cell infect pathogen case gene therapi virus use gene therapi
virus need bind specif cell surfac receptor enter cell cell express specif receptor
viru transduc deliv gene cell shall continu build data figur sinc
standard definit tropism literatur academ her/hi view level binding/entri
constitut tropism buy-rat good posit space given exclus proprietari right
recombin aav vector wide rang tropism per figur
addit though method still evolv rang wide note aav product seem
fewer issu immunogen per figur attract partner due robust ip posit
page
cnsheartliverlungkidneypancreasretinaskeletalmusclevascular confirmtropictropictropictropiccould confirmtropiccould confirm
chardan knowledg never use human clinic studi
figur immunogen studi suggest wide rang result newer vector perform better
gene edit somat gene therapi modifi genet materi
gene edit engin nucleas serv modifi defect gene gene edit dna cell directli
insert delet replac use engin nucleas molecular scissor figur engin nucleas fall
crispr system engin meganucleas re-engin home endonucleas per
figur particular see ampl media attent due abil alter germlin cell
sander jeong natur biotechnolog chardan
figur gene edit insert delet replac chromosom dna patient cell
page
preval neutral antibodi aav serotyp healthi subject china implic gene therapi vaccin use preval neutral antibodi adeno-associ viru capsid reduc young japanes serum igg neutral factor adeno-associ viru aav type healthi popul implic gene therapi use aav immun respons
gene edit potenti transform gene therapi landmark result great ormond street hospit
london demonstr potenti gene edit profoundli chang gene therapi landscap case infant
patient acut lymphoblast leukemia fail multipl round therapi patient given
engin immun cell design destroy leukem cell crucial gene edit talen perform
modifi gene engin immun cell evad recognit destruct patient immun system
proof-of-concept case demonstr capabl gene edit provid shelf gene therapi
potenti transform space
adapt genecopoeia addgen chardan
figur gene edit method comparedth profil make ideal system varieti gene therapi indic
rnai somat gene therapi silenc gene express
rnai function reduc abund aberr gene product rnai small rna duplex target specif
gene deliv cell upon deliveri small rna protein cell call argonaut recogn
destroy rna specif target gene per figur serv silenc target gene correspond
protein longer produc
page
zinc-fing nucleas zfn transcription-activator-lik effector nucleas meganucleasestechnologyprotein dna nucleas recognit activ tailor edit specif genesprotein dna nucleas recognit activ tailor edit specif genesprotein dna nucleas activ guid rna recogn edit specif genesprotein dna nucleas recognit activ tailor edit specif genesadvantagesfirst gene edit technologyeasi afford zfn meganucleaseseasi afford methodsimprov specif gene edit methodslimitationspotenti non-specif gene editingexpensive/difficult design inefficientexpensive/difficult design inefficientexpensive/difficult design potenti non-specif gene edit
adapt obrochta igtrcn chardan
figur rna interfer rnai appli small rna target specif gene suppress rna step protein product
rnai potenti durabl therapeut gene therapi phase ii clinic trial result medicin compani
buy buy present american colleg cardiolog confer
washington dc strongli support use rnai therapi long-term gene therapi trial inclisiran first-in-class
rnai therapi inhibit synthesi led reduct low-dens lipoprotein-cholesterol ldl-c level
strikingli data indic singl dose inclisiran gener durabl reduct ldl-c
least month suggest inclisiran could given time per year stabl suppress target gene
provid real potenti rnai therapi serv durabl gene therapi
gene therapi approach potenti substanti overlap vector gene edit rnai gene therapi
strategi outlin mutual exclus multipl potenti area intersect clinic develop
exampl vector gene therapi design incorpor gene edit system like
rnai technolog intersect present signific opportun approach combin use
specif aav serotyp achiev tissue-specif tropism rnai therapi
futur direct winner loser determin along certain dimens
despit posit sentiment gene therapi still experiment compani yet achiev fda ema
approv gene therapi highlight key challeng go forward
regulatori framework still evolv even case glybera europ approv condit
market author given except circumst product later voluntarili
withdrawn market due think lacklust demand margin efficaci
risk immun toxic viral vector still present although less current vector toxic could
come activ cell viral vector might reduc efficaci
page
number theoret safeti risk need elucid review academ literatur suggest
number theoret risk includ gene silenc transgen express even cell contain
phenotox overexpress donat gene lead toxic insert mutagenesi random
integr gene promot cancer format horizont transmiss donat dna vector shed
blood urin semen bodili fluid possibl transmit other vertic transmiss
unintend germlin transmiss gene thu far aav vector seem screen well risk
manufactur viral vector industri scale challeng good manufactur principl
adequ work yet rang gene therapi product develop
gene edit rnai therapi nascent stage clinic develop despit intrigu result case
studi initi clinic trial still earli clinic develop gene edit rnai viabl gene
therapi gene edit rnai therapi yet receiv regulatori approv
gene therapi like succeed treatment requir transduct fraction bodi cell
gene therapi greater chanc success singl genet defect requir repair
fraction bodi cell deliveri clot factor transgen fraction blood cell contrast gene therapi
requir repair larg fraction bodi cell deliveri tumor suppressor gene cell tumor
like face challeng effect therapeut respons
viabl busi model yet valid gene therapi due factor sever condit pursu
gene therapi extrem rare thu make commerci market size rather limit price extrem high
strimv money-back guarante luxturna treat eye gene therapi work
also gene therapi intent cur singl infus may reach cure thu limit potenti continu
revenu administr unless new pay-for-perform model establish
page
figur solid biosciencesincom statement million except ep
page
million except gener incom incom incom incom incom attribut common basic dilut ep attribut common ep ep attribut common ep pro forma distribut cash shareholdersdividend size incom gener incom incom incom incom incom attribut common
sale key product
figur solid biosciencesproduct revenu licens revenu million
page
therapeut pi/ii gt iv pc mab pipelin pipelin yoy product yoy
figur solid biosciencesdiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product cash fiscal year end fiscal year end project discount pipelin project discount per cash per dilut share price valu per perpetu growth market cap solid bioscienc inc
